SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Fidler, I.J. and Ellis, L.M. (2000) Chemotherapeutic Drugs—More Really Is Not Better. Nature Medicine, 6, 500-502.
http://dx.doi.org/10.1038/74969

has been cited by the following article:

  • TITLE: Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing

    AUTHORS: Aaron J. Smith, John Oertle, Dino Prato

    KEYWORDS: Metronomic Dosing, Chemotherapy, Multidrug Resistance, Neutropenia, Lymphocytopenia, Insulin, Biomarkers, Cognitive Changes

    JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.5, May 27, 2015

    ABSTRACT: Metronomic dosing of chemotherapy was introduced in the early 2000s and has since gained recognition as a potential game changer in the manner of which chemotherapy can be administered. There are several known candidates for metronomic dosing of chemotherapy with the potential for many more to be elucidated in the future. Minimized overall side effects, longer durations of treatment, potential minimization of multidrug resistance (MDR) mutations, potential less refractory responses, and the potential to safely use more than one chemotherapy treatments also make metronomic dosing of chemotherapy attractive. Metronomic dosing reduces common side effects and has the potential to reduce neutropenia, lymphocytopenia, and cognitive changes associated with maximum tolerated dosages (MTD). Methods of enhancing chemotherapy including fasting and administration of insulin are also discussed. Metronomic dosing combined with a patient’s molecular profile derived from biomarkers is particularly exciting. It holds significant potential with regard to administrating the most relevant chemotherapies and offers maximal beneficial results.